(922.5) A combinatorial chemical epigenetics screen identifies an off-target modulation of drug transporter function

Poster Board Number: B196

Samir Barghout (Structural Genomics Consortium, University of Toronto, Structural Genomics Consortium, University of Toronto), Yifan Yu (Structural Genomics Consortium, University of Toronto, Structural Genomics Consortium, University of Toronto), Cheryl Arrowsmith (Structural Genomics Consortium, University of Toronto, Structural Genomics Consortium, University of Toronto), Dalia Barsyte-Lovejoy (Structural Genomics Consortium, University of Toronto, Structural Genomics Consortium, University of Toronto)

Anticancer drug response is determined by genetic and epigenetic mechanisms. To identify the epigenetic regulators of anticancer drug response, we conducted a chemical epigenetics screen using chemical probes that target different epigenetic modulators. In this screen, we tested 31 epigenetic probes in combination with 14 mechanistically diverse anticancer agents and measured the viability in A549 lung adenocarcinoma cells by the Resazurin assay. We identified 6 epigenetic probes that significantly potentiated the cytotoxicity of TAK-243, a first-in-class ubiquitin-activating enzyme (UBA1) inhibitor evaluated in several solid and hematologic malignancies. These probes include TP-472, GSK-864, A-196, UNC1999, SGC-CBP30 and PFI-4, and target BRD9/7, mutant IDH1, SUV420H1/H2, EZH2/H1, p300/CBP and BRPF1B, respectively. To validate the screen results, we assessed the viability after combination of TAK-243 and the identified probes and observed 4- to 30-fold potentiation of TAK-243 cytotoxicity in myeloma cells. Moreover, we tested the identified probes in 13 additional cell lines and observed profound potentiation. Upon combination with a panel of anticancer agents, epigenetic probes did not potentiate their cytotoxicity suggesting the observed effects are selective for TAK-243. In contrast to epigenetic probes, negative chemical controls did not have a significant impact on TAK-243 cytotoxicity. As assessed by immunoblotting, potentiation of TAK-243 cytotoxicity was associated with reduced ubiquitylation and induction of apoptosis. Using the cellular thermal shift assay (CETSA), UBA1 displayed increased engagement with TAK-243, suggesting the epigenetic probes enhanced intracellular drug accumulation. Mechanistically, the epigenetic probes exerted their potentiation by inhibiting the efflux transporter ABCG2 without inducing significant changes in ubiquitylation pathways or ABCG2 expression levels. Additionally, the identified probes shared significant chemical scaffold similarities with TAK-243. Based on the screen results, we developed a cell-based assay that exploits TAK-243 and ABCG2-overexpressing cells to reliably quantify the ABCG2-inhibitory activity of novel compounds. In conclusion, our study identifies epigenetic probes that profoundly potentiate TAK-243 cytotoxicity through off-target ABCG2 inhibition. We also provide experimental evidence of the inability of negative controls to exclude a subset of off-target effects of chemical probes. Finally, we have developed a robust cell-based assay that can quantitatively evaluate ABCG2 inhibition by drug candidates.

Support or Funding Information

S.H.B is a Mitacs Elevate Fellow. The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Pfizer and Takeda.